Eisai’s Cheung, head of U.S. and Leqembi lead, retiring

Ivan Cheung, who led the development and launch preparations for newly approved Alzheimer’s drug Leqembi lecanemab-irmb, is retiring as chairman and CEO of Eisai Inc., the U.S. unit of  Eisai Co. Ltd. (Tokyo:4523), effective July 31. SVP and CFO Tatsuyuki Yasuno will succeed him, becoming SVP, acting president, Americas region and acting chairman & CEO of the U.S. unit.

Among other changes at the Japanese pharma, SVP, Chief Strategy & Planning Officer and Chief Ecosystem Officer Keisuke Naito will take on the role of acting global Alzheimer’s officer. Group Officer, Head of Corporate Finance and Accounting Headquarters Mitsuru Shomon will become the new CFO. The new chief investor relations officer is Masatomi Akana, who also holds the titles of SVP, chief government relations officer, global value & access, general affairs and environment affairs and Japan subsidiary management. The company also named Toshitaka Asano as VP, head of corporate planning and business development headquarters...